Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  American Journal of Managed Care

• Publication date

  2005-09-14

• Fields of study

  Medicine

• Identifiers
  PMID 16180960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trends in prevalence, awareness, treatment and control of hypertension in urban communities in Chile

  2007cited by this paper
• Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.

  2005cited by this paper
• Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆

  2004cited by this paper
• Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial

  2004cited by this paper
• Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.

  2004cited by this paper
• Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.

  2004cited by this paper
• Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

  2004cited by this paper
• Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.

  2004cited by this paper
• Guidelines for Hypertension: Are Quality-Assurance Measures on Target?

  2004cited by this paper
• Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.

  2003cited by this paper
• Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002)

  2003cited by this paper
• Long-term persistence with antihypertensive drugs in new patients

  2002cited by this paper
• The changing face of hypertension: is systolic blood pressure the final answer?

  2002influential reference
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Impact of high-normal blood pressure on the risk of cardiovascular disease.

  2002influential reference
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

  2002cited by this paper
• A population-based European cohort study of persistence in newly diagnosed hypertensive patients

  2002cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• Antihypertensive persistence and drug class.

  2002cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY

  2001cited by this paper
• Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.

  2001influential reference
• Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.

  2000influential reference
• SPECIAL REPORT Preserving Renal Function in Adults With Hypertension and Diabetes: A Consensus Approach

  2000cited by this paper
• Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2000cited by this paper
• Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

  2000influential reference
• Angiotensin II antagonists for hypertension: are there differences in efficacy?

  2000cited by this paper
• Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.

  1999cited by this paper
• A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

  1995cited by this paper
• Blood Pressure (Systolic and Diastolic) and Risk of Fatal Coronary Heart Disease

  1989cited by this paper
• Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial.

  1988cited by this paper
• Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the multiple risk factor intervention trial

  1988cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Efficacy and safety of amlodipine/valsartan/hydrochlorothiazide single pill combination in Egyptian patients with hypertension uncontrolled on any dual therapy: an observational study

  2020cites this paper
• Simultaneous determination of metolazone and valsartan in plasma by on-line SPE coupled with liquid chromatography/tandem mass spectrometry

  2017cites this paper
• Circadian Clocks: Role in Health and Disease

  2016cites this paper
• Chronotherapy of Blood Pressure Medications to Improve Management of Hypertension and Reduce Vascular Risk

  2016cites this paper
• Antihypertensive drug combinations

  2014cites this paper
• Clinical Inertia in Poorly Controlled Elderly Hypertensive Patients: A Cross-Sectional Study in Spanish Physicians to Ascertain Reasons for Not Intensifying Treatment

  2013cites this paper
• Administration-Time Differences in Effects of Hypertension Medications on Ambulatory Blood Pressure Regulation

  2013cites this paper
• Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma

  2013cites this paper
• Chronotherapy of hypertension with combination treatment.

  2013cites this paper
• Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma

  2013cites this paper
• Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

  2012cites this paper
• Chronotherapy With Valsartan/Hydrochlorothiazide Combination in Essential Hypertension: Improved Sleep-Time Blood Pressure Control With Bedtime Dosing

  2011cites this paper
• Aliskiren‐based stepped‐care treatment algorithm provides effective blood pressure control

  2011cites this paper
• Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches

  2011cites this paper
• 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension

  2011cites this paper
• Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure

  2010cites this paper
• CHRONOTHERAPY WITH VALSARTAN/AMLODIPINE FIXED COMBINATION: IMPROVED BLOOD PRESSURE CONTROL OF ESSENTIAL HYPERTENSION WITH BEDTIME DOSING

  2010cites this paper
• Prevalence of High‐Risk Cardiovascular Conditions and the Status of Hypertension Management Among Hypertensive Adults 65 Years and Older in the United States: Analysis of a Primary Care Electronic Medical Records Database

  2010cites this paper
• Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy

  2009cites this paper
• A Randomized Clinical Trial

  2009cites this paper
• Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety

  2009cites this paper
• Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension

  2007cites this paper
• [Knowledge and implementation of cardiovascular risk clinical practice guidelines by general practitioners and specialists].

  2006cites this paper
• Peer reviewed publications in 2005.

  2006cites this paper
• Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas

  2006cites this paper
• Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales

  2006cites this paper